More severe CTE stage and nigral pathology seen for participants with parkinsonism versus those without parkinsonism
TUESDAY, July 16, 2024 (HealthDay News) — Multiple substantia nigra (SN) pathologies are associated with parkinsonism, according to a study published online July 15 in JAMA Neurology.
Jason W. Adams, Ph.D., from the Boston University Alzheimer”s Disease and CTE Center, and colleagues examined the frequency of parkinsonism in individuals with chronic traumatic encephalopathy (CTE) in a cross-sectional study.
The researchers found that parkinsonism occurred frequently in individuals with CTE, occurring in 24.7 percent of 481 male brain donors with neuropathologically diagnosed CTE. Compared with those without parkinsonism, those with parkinsonism had a more severe CTE stage (e.g., stage IV: 29.4 versus 10.8 percent) and nigral pathology (neurofibrillary tangles [NFTs]: 42.7 versus 29.9 percent; neuronal loss: 52.1 versus 17.1 percent; Lewy bodies [LBs]: 24.1 versus 5.8 percent). Associations were seen for years of contact sports participation with substantia nigra (SN) NFTs and neuronal loss. Associations were also seen for nigral neuronal loss and LBs with parkinsonism. SN neuronal loss was associated with SN LBs, SN NFTs, and arteriolosclerosis. A regression analysis demonstrated that SN NFTs and neuronal loss mediated the association between years of play and parkinsonism in the context of CTE among American football players.
“The findings suggest that extensive repetitive head injury is associated with parkinsonism through increased tau pathology and neuronal loss, even in the absence of Lewy pathology,” the authors write.
Several authors disclosed ties to the biopharmaceutical and sports industries.
Abstract/Full Text (subscription or payment may be required)
Estrogen Hormone Treatment May Be Beneficial for Brain Fog Symptoms in Menopausal Women
Brain Abnormalities Identified in Children at Risk for Schizophrenia
Extreme Heat Linked to 33 Clinically Reportable Diagnoses
Cortical Atrophy in Early-Onset Alzheimer Disease Signature Can Predict Progression to Dementia
Exercise Link to Dementia Varies by Physical Activity Domain
Real-World ARIA Incidence With Lecanemab Aligns With Clinical Trial Findings
Imaging Turnaround Time Increased From 2023 to 2024